RecruitingPhase 3NCT07573969

Adding Dexmedetomidine Versus Ketamine to Bupivacaine in Fluoroscopy Guided Caudal Analgesia for Lumbosacral Surgeries

Effect of Adding Dexmedetomidine Versus Ketamine to Bupivacaine in Fluoroscopy Guided Caudal Analgesia for Lumbosacral Surgeries Under General Anaesthesia; a Randomised Controlled Double Blinded Study


Sponsor

Ain Shams University

Enrollment

72 participants

Start Date

May 1, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This study will evaluate the effect of adding dexmedetomidine to bupivacaine compared to ketamine in the caudal block on perioperative analgesia in patients undergoing lumbosacral surgeries under general anesthesia.


Eligibility

Min Age: 21 YearsMax Age: 60 Years

Inclusion Criteria4

  • Age 21-60 years.
  • Sex: Both sexes.
  • American Society of Anesthesiologists (ASA) Physical Status Class-I and II.
  • Scheduled for lumbosacral surgery under General Anesthesia.

Exclusion Criteria5

  • Declining to give written informed consent or patients with significant cognitive dysfunction that hinders informed consent.
  • History of allergy to the medications used in the study.
  • Contraindications to regional anesthesia (including coagulopathy and local infection).
  • History of recent analgesic intake or abuse.
  • Pregnancy or lactating mothers.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGroup C (plain bupivacaine (0.125%))

The patients will receive 20ml plain bupivacaine (0.125%) in the caudal block

DRUGGroup D (plain bupivacaine (0.125%) + 2μg/kg dexmedetomidine)

The patients will receive 20ml plain bupivacaine (0.125%) + 2μg/kg dexmedetomidine in the caudal block

DRUGGroup K (plain bupivacaine (0.125%) + 1mg/kg ketamine)

The patients will receive 20ml plain bupivacaine (0.125%) + 1mg/kg ketamine in the caudal block


Locations(1)

Ain Shams University hospitals

Cairo, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07573969


Related Trials